Abbott Laboratories (ABT): Today's Featured Drugs Winner - TheStreet

Abbott Laboratories

(

ABT

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1%. By the end of trading, Abbott Laboratories rose 53 cents (0.8%) to $64.65 on average volume. Throughout the day, 5.6 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.1 million shares. The stock ranged in a price between $64.46-$65 after having opened the day at $64.78 as compared to the previous trading day's close of $64.12. Other companies within the Drugs industry that increased today were:

XenoPort

(

XNPT

), up 23.7%,

iBio

(

IBIO

), up 13.2%,

Synta Pharmaceuticals

(

SNTA

), up 12.2%, and

Sangamo BioSciences

(

SGMO

), up 9.1%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $100.6 billion and is part of the

health care

sector. The company has a P/E ratio of 20.8, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 13.7% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Aoxing Pharmaceutical Company

(

AXN

), down 21.2%,

StemCells

(

STEM

), down 13.2%,

China Pharma

(

CPHI

), down 11.8%, and

Meridian Bioscience

(

VIVO

), down 9.2%, were all laggards within the drugs industry with

Warner Chilcott

(

WCRX

) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null